Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Environmental Science & Technology

Deriving Organism-Relevant Nanoparticle Safety Exposure Limits from In Vitro Toxicity Data

  1. 1Empa, Swiss Federal Laboratories for Materials Science and Technology, Nanomaterials in Health Laboratory, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland
  2. 2Empa, Swiss Federal Laboratories for Materials Science and Technology, Technology and Society Laboratory, Lerchenfeldstrasse 5, 9014 St. Gallen, Switzerland

Abstract

Establishing human safety limits of engineered nanoparticles remains a challenge. In vitro assays have become a major toxicity data resource, driven by the demand for new approach methodologies (NAMs) that reduce animal testing. However, robust tools that bridge in vitro data with in vivo outcomes are still lacking. Here, we present an integrated computational framework using physiologically based pharmacokinetic (PBPK) modeling to derive organism-level BMD10-based dose estimates directly from in vitro liver toxicity data. For 4 nondissolvable nanoparticles (TiO2, SiO2, Au, and graphene oxide), we curated in vitro toxicity data sets spanning 7 liver-relevant cell systems (5 human and 2 mouse) across 24 assays and estimated in vitro effect thresholds using the benchmark dose for a 10% response (BMD10). Mouse in vitro BMD10 values were then reverse-translated into predicted BMD10 IVIVE values using a validated mouse PBPK model and benchmarked against available mouse-derived in vivo effect threshold (BMD10 eq) data to ensure consistency. The resulting nanoparticle-specific BMD10 IVIVE ranges showed qualitative concordance with animal-derived reference doses, supporting the biological plausibility of these screening-level dose estimates. We further applied the same workflow to human liver cell systems to derive human-relevant BMD10-based points of departure. This approach establishes a scalable and prospective animal-free workflow for human nanoparticle risk assessments, overcoming a critical translational gap.

Related

  1. Environmentally relevant PFBS exposure triggers colonic inflammation through PPAR-mediated mitochondrial dysfunction and cGAS–STING activation
    Minming Chen, Xianting Jiao, Chenyin Dong +5
    Ecotoxicology and Environmental SafetyPeer-reviewedCC BYFull textEnvironmental chemistryDOAJ
  2. Sub‑chronic PFOA exposure at human‑relevant increasing doses in male mice: Role of stress‑induced gut barrier disruption in shaping intestinal and hepatic responses under high-dose conditions
    Anaïs Bodon, Rémi Dagès, Valérie Bézirard +12
    Environment InternationalPeer-reviewedCC BYFull textEnvironmental chemistryHAL
  3. Lorentz-Covariant Bi-Photonic Kinematics: Deriving Optical Polarization and the Born Rule from Internal Constrained Dynamics
    Matthew Minus
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  4. Deriving General Energy Predictors for Pnictogen Bonding
    Jan Langwald, Antonio Frontera
    Chemistry (Weinheim an Der Bergstrasse, Germany)Peer-reviewedCC BY 4.0Full textPhysical chemistryPMC
  5. Deriving New Model Hamiltonians for [2Fe-2S] Iron-Sulfur Clusters
    Wyatt A. Gibbs, David Wilian Oliveira de Sousa, Elvira R. Sayfutyarova
    ChemRxivPreprintCC BYGeneral chemistryChemRxiv
BibTeX
@article{wu2026deriving,
  title = {{Deriving Organism-Relevant Nanoparticle Safety Exposure Limits from In Vitro Toxicity Data}},
  author = {Jimeng Wu and Peter Wick and Bernd Nowack},
  journal = {Environmental Science \& Technology},
  year = {2026},
  month = oct,
  doi = {10.1021/acs.est.6c13254},
  url = {https://doi.org/10.1021/acs.est.6c13254},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Deriving Organism-Relevant Nanoparticle Safety Exposure Limits from In Vitro Toxicity Data
AU  - Jimeng Wu
AU  - Peter Wick
AU  - Bernd Nowack
PY  - 2026
DA  - 2026/10/28
JO  - Environmental Science & Technology
DO  - 10.1021/acs.est.6c13254
UR  - https://doi.org/10.1021/acs.est.6c13254
AB  - Establishing human safety limits of engineered nanoparticles remains a challenge. In vitro assays have become a major toxicity data resource, driven by the demand for new approach methodologies (NAMs) that reduce animal testing. However, robust tools that bridge in vitro data with in vivo outcomes are still lacking. Here, we present an integrated computational framework using physiologically based pharmacokinetic (PBPK) modeling to derive organism-level BMD10-based dose estimates directly from in vitro liver toxicity data. For 4 nondissolvable nanoparticles (TiO2, SiO2, Au, and graphene oxide), we curated in vitro toxicity data sets spanning 7 liver-relevant cell systems (5 human and 2 mouse) across 24 assays and estimated in vitro effect thresholds using the benchmark dose for a 10% response (BMD10). Mouse in vitro BMD10 values were then reverse-translated into predicted BMD10 IVIVE values using a validated mouse PBPK model and benchmarked against available mouse-derived in vivo effect threshold (BMD10 eq) data to ensure consistency. The resulting nanoparticle-specific BMD10 IVIVE ranges showed qualitative concordance with animal-derived reference doses, supporting the biological plausibility of these screening-level dose estimates. We further applied the same workflow to human liver cell systems to derive human-relevant BMD10-based points of departure. This approach establishes a scalable and prospective animal-free workflow for human nanoparticle risk assessments, overcoming a critical translational gap.
SN  - 0013-936X
SN  - 1520-5851
ER  -